bioAffinity Technologies (bioAffinity Technologies) Risk Assessment

View and export this data going back to 2022. Start your Free Trial

What is bioAffinity Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of bioAffinity Technologies is: No Data: Cannot be evaluated.

Competitive Comparison of bioAffinity Technologies's Risk Assessment

For the Diagnostics & Research subindustry, bioAffinity Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bioAffinity Technologies's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's Risk Assessment falls into.

bioAffinity Technologies (NAS:BIAF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

bioAffinity Technologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of bioAffinity Technologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

bioAffinity Technologies (bioAffinity Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » bioAffinity Technologies Inc (NAS:BIAF) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257

Website

https://www.bioaffinitytech.com

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.

Executives

Roby Joyce	director	22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Xavier Trinidad Reveles	officer: Chief Operating Officer	22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Michael Philip Dougherty	officer: Chief Financial Officer	2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232
James Michael Edwards	officer: Chief Financial Officer	30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015
Peter S Knight	director	6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060
Steven Girgenti	director, officer: Executive Chairman	C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Robert A. Anderson	director	70 DOPPLER, IRVINE CA 92618
Gary D Rubin	director, 10 percent owner	2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431
Stuart Diamond	director	498 SEVENTH AVE, NEW YORK NY 10018
Maria Zannes	director, officer: President, CEO	19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256
Harvey Sandler Revocable Trust	10 percent owner	21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180
Mohsin Y Meghji	director	C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016
Vivienne I Rebel	officer: EVP, Chief Sci. & Med. Officer	8922 APACHE TRAIL, SAN ANTONIO TX 78255
Timothy P Zannes	officer: Secretary, EVP, Gen. Counsel	1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106
Nathan M Perlmutter	10 percent owner	28 PARRISH POND LANE, SOUTHAMPTON NY 11968